Tatsuo Okui

Prof. Tatsuo Okui


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
JSJingjing Sha
Jingjing Sha
YBYunpeng Bai
Yunpeng Bai
Huy NgoHuy Ngo
Huy Ngo
TOTatsuo Okui
Tatsuo Okui
TKTakahiro Kanno
Takahiro Kanno
The increasing incidence of resistance to chemotherapeutic agents has become a major issue in the treatment of oral cancer (OC). Epithelial-mesenchymal transition (EMT) has attracted a great deal of attention in recent years with regard to its relation to the mechanism of chemotherapy drug resistance. EMT-activating transcription factors (EMT-ATFs), such as Snail, TWIST, and ZEB, can activate several different molecular pathways, e.g., PI3K/AKT, NF-κB, and TGF-β. In contrast, the activated oncological signal pathways provide reciprocal feedback that affects the expression of EMT-ATFs, resulting in a peritumoral extracellular environment conducive to cancer cell survival and evasion of the immune system, leading to resistance to multiple chemotherapeutic agents. We present an overview of evidence-based chemotherapy for OC treatment based on the National Comprehensive Cancer Network (NCCN) Chemotherapy Order Templates. We focus on the molecular pathways involved in drug resistance related to the EMT and highlight the signal pathways and transcription factors that may be important for EMT-regulated drug resistance. Rapid progress in antitumor regimens, together with the application of powerful techniques such as high-throughput screening and microRNA technology, will facilitate the development of therapeutic strategies to augment chemotherapy.

25 August 2021 in Journal of Bone Oncology
Verified
Journal Article
Open access
TYToshiyuki Yoneda
Toshiyuki Yoneda
MHMasahiro Hiasa
Masahiro Hiasa
TOTatsuo Okui
Tatsuo Okui
KHKenji Hata
Kenji Hata
• Bone is densely innervated by sensory nerves. • Excitation of the sensory nerve nociceptor TRPV1 induces cancer-associated bone pain and promotes cancer progression in bone. • Sensory nerve TRPV1 is a therapeutic target for cancer progression and associated bone pain.

19 August 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
TOTatsuo Okui
Tatsuo Okui
YMYuhei Matsuda
Yuhei Matsuda
MKMasaaki Karino
Masaaki Karino
KHKatsumi Hideshima
Katsumi Hideshima
TKTakahiro Kanno
Takahiro Kanno
The World Health Organization reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is caused by respiratory droplets and aerosols from the oral cavity of infected patients. The angiotensin-converting enzyme 2 (ACE2) is considered the host functional protein for SARS-CoV-2 infection. In this article, we first revealed that the positive proportion of ACE2 expression in gingival cells collected from the gingival sulcus was increased to the same level as the tongue. Our data demonstrate that cells in the gingival sulcus may be a new entry point for the SARS-CoV-2 virus via a high expression of ACE2. In addition, we first evaluated the expression of ACE2 in various sites of the oral cavity with noninvasive, convenient liquid-based cytology. The liquid-based cytology evaluation of oral tissue may provide a novel preventive medical avenue against COVID-19.

26 December 2021 in Materials
Verified
Journal Article
Open access
PDF file
Huy NgoHuy Ngo
Huy Ngo
YBYunpeng Bai
Yunpeng Bai
JSJingjing Sha
Jingjing Sha
SIShinji Ishizuka
Shinji Ishizuka
ETErina Toda
Erina Toda
TKTakahiro Kanno
Takahiro Kanno
The advent of bioresorbable materials to overcome limitations and replace traditional bone-reconstruction titanium-plate systems for bone fixation, thus achieving greater efficiency and safety in medical and dental applications, has ushered in a new era in biomaterial development. Because of its bioactive osteoconductive ability and biocompatibility, the forged composite of uncalcined/unsintered hydroxyapatite and poly L-lactic acid (u-HA/PLLA) has attracted considerable interest from researchers in bone tissue engineering, as well as from clinicians, particularly for applications in maxillofacial reconstructive surgery. Thus, various in vitro studies, in vivo studies, and clinical trials have been conducted to investigate the feasibility and weaknesses of this biomaterial in oral and maxillofacial surgery. Various technical improvements have been proposed to optimize its advantages and limit its disadvantages. This narrative review presents an up-to-date, comprehensive review of u-HA/PLLA, a bioactive osteoconductive and bioresorbable bone-reconstruction and -fixation material, in the context of oral and maxillofacial surgery, notably maxillofacial trauma, orthognathic surgery, and maxillofacial reconstruction. It simultaneously introduces new trends in the development of bioresorbable materials that could used in this field. Various studies have shown the superiority of u-HA/PLLA, a third-generation bioresorbable biomaterial with high mechanical strength, biocompatibility, and bioactive osteoconductivity, compared to other bioresorbable materials. Future developments may focus on controlling its bioactivity and biodegradation rate and enhancing its mechanical strength.

1 October 2021 in Oral Oncology
Verified
Journal Article
Closed access
YMYuhei Matsuda
Yuhei Matsuda
TOTatsuo Okui
Tatsuo Okui
MKMasaaki Karino
Masaaki Karino
NANoriaki Aoi
Noriaki Aoi
SOSatoe Okuma
Satoe Okuma
TKTakahiro Kanno
Takahiro Kanno

1 July 2010
Verified
Journal Article
Closed access
SISachiko Isowa
Sachiko Isowa
TSTsuyoshi Shimo
Tsuyoshi Shimo
SISoichiro Ibaragi
Soichiro Ibaragi
NKNaito Kurio
Naito Kurio
TOTatsuo Okui
Tatsuo Okui
ASAkira Sasaki
Akira Sasaki